A Phase 2 trial of BOLD 100 in combination with a standard-of-care agent in the treatment of bladder cancer
Latest Information Update: 17 May 2022
At a glance
- Drugs BOLD 100 (Primary) ; Antineoplastics
- Indications Bladder cancer
- Focus Therapeutic Use
Most Recent Events
- 17 May 2022 New trial record
- 10 May 2022 According to a Bold Therapeutics media release, the company is actively seeking global development partners in Q4 2022 to support this two additional parallel Phase 2 studies.